NMRD (Nemaura Medical) EBITDA: $-4.50 Mil (TTM As of Dec. 2023)


What is Nemaura Medical EBITDA?

Nemaura Medical NMRD EBITDA is $-4.50 Mil as of Dec. 2023.

Nemaura Medical's EBITDA for the three months ended in Dec. 2023 was $-0.16 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.50 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Nemaura Medical's EBITDA per Share for the three months ended in Dec. 2023 was $-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

Nemaura Medical  (OTCPK:NMRD) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Nemaura Medical EBITDA Related Terms


Nemaura Medical EBITDA Historical Data

* Premium members only.

The historical data trend for Nemaura Medical's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nemaura Medical EBITDA Chart

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.44 -4.72 -4.49 -7.34 -7.29

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -2.25 -1.85 -0.25 -0.16

NMRD vs THMO, MOTS, ABT: EBITDA Comparison

For the Medical Devices subindustry, Nemaura Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nemaura Medical EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nemaura Medical's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Nemaura Medical's EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Nemaura Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2023, Nemaura Medical's EBITDA was $-7.29 Mil.

Nemaura Medical's EBITDA for the quarter that ended in Dec. 2023 is calculated as

Nemaura Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, Nemaura Medical's EBITDA was $-0.16 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-4.50 Mil mean?
Nemaura Medical (NMRD) has a EBITDA of $-4.50 Mil as of Dec. 2023. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Nemaura Medical.
Is Nemaura Medical's EBITDA too high?
Nemaura Medical's current EBITDA is $-4.50 Mil.
How does Nemaura Medical's EBITDA compare to THMO and MOTS?
Nemaura Medical's EBITDA of $-4.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Nemaura Medical. Nemaura Medical's current EBITDA is $-4.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nemaura Medical stock overvalued right now?
Nemaura Medical (NMRD) has a current EBITDA of $-4.50 Mil. The current EBITDA is $-4.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Nemaura Medical (NMRD), the current EBITDA is $-4.50 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nemaura Medical Business Description

Address 57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.